Literature DB >> 15122589

Serologic detection of diffuse large B-cell lymphoma-associated antigens.

Amanda P Liggins1, Barbara A Guinn, Chris S Hatton, Karen Pulford, Alison H Banham.   

Abstract

Diffuse large B-cell lymphoma (DLBCL) accounts for 30-40% of all adult non-Hodgkin's lymphomas, yet the understanding of its underlying genetic abnormalities remains poor. Our present study used the serological analysis of recombinant cDNA expression libraries (SEREX) technique to identify DLBCL-associated antigens. SEREX screening of testis libraries has previously identified cancer-testis antigens (CTAs) that may act as disease-specific targets for immunotherapy. Screening a testis cDNA expression library with serum from a DLBCL patient identified a total of 94 positive clones, representing 28 distinct antigens. Two of these antigens were novel, 8 were previously uncharacterised, and the remainder were proteins of known function. Screening of the antigens with sera from DLBCL (n = 10), acute myeloid leukaemia (AML, n = 10) and chronic myeloid leukaemia (CML, n = 10) patients, alongside normal healthy donor controls (n = 20), revealed that 7 of the antigens were recognised by DLBCL sera but not normal donor sera, whilst 2 of these antigens were also recognised by leukaemic sera. Some of the genes identified here were already known to be transcribed in DLBCL. The mRNA expression of the majority of the remaining antigens was confirmed in DLBCL cell lines using reverse-transcriptase PCR (RT-PCR). Our study identified a number of DLBCL associated antigens that may be suitable as prognostic/diagnostic markers and/or for the immunotherapy of haematologic malignancies. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15122589     DOI: 10.1002/ijc.20170

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  7 in total

1.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

2.  Proteome-based analysis of serologically defined tumor-associated antigens in cutaneous lymphoma.

Authors:  Michael Forgber; Sylke Gellrich; Tumenjargal Sharav; Wolfram Sterry; Peter Walden
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

3.  An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Authors:  Nicola Hardwick; Sarah Buchan; Wendy Ingram; Ghazala Khan; Gisella Vittes; Jason Rice; Karen Pulford; Ghulam Mufti; Freda Stevenson; Barbara-ann Guinn
Journal:  Cancer Immun       Date:  2013-07-15

Review 4.  Active immunotherapy: current state of the art in vaccine approaches for NHL.

Authors:  M Lia Palomba
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

5.  Identification and characterization of peripheral T-cell lymphoma-associated SEREX antigens.

Authors:  Christopher D O Cooper; Charles H Lawrie; Amanda P Liggins; Graham P Collins; Christian S R Hatton; Karen Pulford; Alison H Banham
Journal:  PLoS One       Date:  2011-08-22       Impact factor: 3.240

6.  A novel diffuse large B-cell lymphoma-associated cancer testis antigen encoding a PAS domain protein.

Authors:  A P Liggins; P J Brown; K Asker; K Pulford; A H Banham
Journal:  Br J Cancer       Date:  2004-07-05       Impact factor: 7.640

Review 7.  New targets for therapy: antigen identification in adults with B-cell acute lymphoblastic leukaemia.

Authors:  Stephanie Jordaens; Leah Cooksey; Laurie Freire Boullosa; Viggo Van Tendeloo; Evelien Smits; Ken I Mills; Kim H Orchard; Barbara-Ann Guinn
Journal:  Cancer Immunol Immunother       Date:  2020-01-22       Impact factor: 6.968

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.